Qiagen N.V. logo

Qiagen N.V. (QIA)

Market Closed
5 Dec, 20:00
40. 41
-0.01
-0.02%
- Market Cap
26.32 P/E Ratio
1.28% Div Yield
363,923 Volume
2.11 Eps
40.41
Previous Close
Day Range
40.33 40.77
Year Range
34.23 47.36
Want to track QIA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 58 days

Summary

QIA closed yesterday lower at €40.41, a decrease of 0.02% from Thursday's close, completing a monthly decrease of -1.83% or €0.75. Over the past 12 months, QIA stock lost -8.21%.
QIA pays dividends to its shareholders, with the most recent payment made on Jul 10, 2025. The next estimated payment will be in In 7 months on Jul 10, 2026 for a total of €0.25.
The last earnings report, released on Nov 05, 2025, missed the consensus estimates by -0.5%. On average, the company has fell short of earnings expectations by -0.16%, based on the last three reports. The next scheduled earnings report is due on Feb 03, 2026.
Qiagen N.V. has completed 3 stock splits, with the recent split occurring on Jan 29, 2025.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NYSE (USD).

QIA Chart

Qiagen (QGEN) Up 6.3% Since Last Earnings Report: Can It Continue?

Qiagen (QGEN) Up 6.3% Since Last Earnings Report: Can It Continue?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Zacks | 2 days ago
Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seekingalpha | 3 days ago
Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seekingalpha | 4 days ago

Qiagen N.V. (QIA) FAQ

What is the stock price today?

The current price is €40.41.

On which exchange is it traded?

Qiagen N.V. is listed on NYSE.

What is its stock symbol?

The ticker symbol is QIA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.28%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Feb 03, 2026.

Has Qiagen N.V. ever had a stock split?

Qiagen N.V. had 3 splits and the recent split was on Jan 29, 2025.

Qiagen N.V. Profile

- Industry
- Sector
Thierry Bernard CEO
XFRA Exchange
NL0012169213 ISIN
NL Country
5,700 Employees
2 Jul 2025 Last Dividend
14 Jul 2000 Last Split
28 Jun 1996 IPO Date

Overview

Founded in 1984 and headquartered in Venlo, the Netherlands, QIAGEN N.V. is a global leader in providing comprehensive solutions that convert biological materials into valuable molecular insights. The company’s innovative portfolio spans a wide range of sectors including molecular diagnostics, academia, pharmaceutical, and applied testing. QIAGEN is dedicated to facilitating the process of acquiring insights from biological samples through its extensive array of technologies and products, designed to support various stages of molecular analysis.

Products and Services

  • Sample Technology Consumables: QIAGEN offers an array of consumables for sample preparation, including nucleic acid stabilization and purification kits tailored for an array of primary sample materials. They provide solutions for manual and automated processing that support genotyping, gene expression analysis, and the assessment of viral and bacterial loads. Technologies include silica membranes and magnetic bead-based approaches.
  • Nucleic Acid Purification Instruments: The company manufactures instruments that enable the purification of nucleic acids along with necessary accessories, helping streamline the preparation process in laboratories.
  • PCR Consumables and Instruments: QIAGEN offers a comprehensive portfolio of PCR consumables, including quantitative PCR (qPCR) and reverse transcription kits designed for various analyses such as gene expression, genotyping, and gene regulation. This category also encompasses a range of PCR instruments, including innovative solutions for digital PCR and qPCR, designed for precision and efficiency.
  • Human ID and Forensics: The company provides assay consumables for human identification (ID) and forensic purposes, including Short Tandem Repeat (STR) assays and tests for detecting food contamination.
  • Assays for Various Diseases and Conditions: QIAGEN develops interferon-gamma release assays for Tuberculosis (TB) testing, along with assays for post-transplant monitoring, viral load determination, prenatal testing, detection of sexually transmitted diseases (STDs), and the Human Papillomavirus (HPV). These offerings are crucial for early detection and monitoring of various conditions and diseases.
  • Genomic Variant Analysis: The company provides assays designed for the detailed analysis of genomic variants, such as mutations, insertions, deletions, and fusions. This is crucial for understanding genetic diseases and tailoring personalized medicine approaches.
  • Next-Generation Sequencing (NGS): QIAGEN’s NGS solutions include predefined and custom gene panels, library preparation kits, and whole genome amplification products. These enable researchers and clinicians to conduct comprehensive genomic studies and leverage sequencing for diagnostics and research purposes.
  • Bioinformatics and Custom Services: In addition to physical products, QIAGEN provides bioinformatics solutions for data analysis and interpretation, as well as custom laboratory and genomic services tailored to meet specific research needs, enabling customers to achieve their unique objectives in molecular analysis.

Contact Information

Address: Hulsterweg 82
Phone: 31 77 355 6600